Lipocine (NASDAQ: LPCN) is one of 297 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Lipocine to related businesses based on the strength of its dividends, profitability, valuation, earnings, analyst recommendations, institutional ownership and risk.

Volatility & Risk

Lipocine has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500. Comparatively, Lipocine’s competitors have a beta of 6.56, indicating that their average share price is 556% more volatile than the S&P 500.

Valuation & Earnings

This table compares Lipocine and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Lipocine N/A -$18.97 million -3.85
Lipocine Competitors $273.19 million $47.94 million -4.26

Lipocine’s competitors have higher revenue and earnings than Lipocine. Lipocine is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Lipocine and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lipocine N/A -64.49% -59.80%
Lipocine Competitors -5,380.01% -437.31% -41.90%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Lipocine and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lipocine 0 0 3 0 3.00
Lipocine Competitors 769 3075 11276 227 2.71

Lipocine currently has a consensus price target of $24.67, suggesting a potential upside of 604.76%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 22.19%. Given Lipocine’s stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than its competitors.

Insider & Institutional Ownership

26.2% of Lipocine shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 11.3% of Lipocine shares are owned by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Lipocine competitors beat Lipocine on 7 of the 12 factors compared.

Lipocine Company Profile

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.